Loeb & Loeb LLP is proud to sponsor the American Conference Institute’s (ACI) 13th Annual Maximizing Pharmaceutical Patent Life Cycles Conference, where partner Mark E. Waddell will serve as conference co-chair and speak on a panel titled "From Product Development to Patent Portfolio Management: Patent Life Cycle Strategies for a Post-AIA World.” Senior Counsel Kathleen M. Gersh will speak on a panel titled "Analyzing Method Claims and the Madness Over Recent and Pending Inducement and Divided Infringement Cases."
From the conference website:
ACI's Maximizing Pharmaceutical Patent Life Cycles conference is the pharmaceutical industry’s leading and integral source for information and analysis on patent life cycle management for both small and now large molecule pharmaceutical products. It is the forum where lawyers, executives and policy makers for brand name and generic manufacturers gather each year to prepare for the life cycle challenges they currently face as well as those which they anticipate.
Selected Agenda
Wednesday, October 10, 2012
8:30AM - 9:30AM - From Product Development to Patent Portfolio Management: Patent Life Cycle Strategies for a Post-AIA World
This panel will explore the relationship between and risk concepts relative to patent portfolio management and patent life cycle planning. Topics addressed include:
Speakers:
George W. Johnston, Hoffmann-LaRoche
Mark E. Waddell, Loeb & Loeb LLP
Thursday, October 11, 2012
10:45AM - 12:00PM - Analyzing Method Claims and the Madness Over Recent and Pending Inducement and Divided Infringement Cases
This panel will examine the link between inducement and divided infringement actions relative to methods of use claims for pharmaceutical patents.
Speakers:
Kathleen M. Gersh, Loeb & Loeb LLP
Edward M. Mathias, Axinn, Veltrop & Harkrider, LLP
Catherine Nyarady, Paul, Weiss, Rifkind, Wharton & Garrison LLP
From the conference website:
ACI's Maximizing Pharmaceutical Patent Life Cycles conference is the pharmaceutical industry’s leading and integral source for information and analysis on patent life cycle management for both small and now large molecule pharmaceutical products. It is the forum where lawyers, executives and policy makers for brand name and generic manufacturers gather each year to prepare for the life cycle challenges they currently face as well as those which they anticipate.
Selected Agenda
Wednesday, October 10, 2012
8:30AM - 9:30AM - From Product Development to Patent Portfolio Management: Patent Life Cycle Strategies for a Post-AIA World
This panel will explore the relationship between and risk concepts relative to patent portfolio management and patent life cycle planning. Topics addressed include:
- Pre-commercialization and R&D considerations relative to patent portfolio and life cycle management in a post-AIA world
- Impact of PPACA on product development and patenting
- Impact of PDUFA on life cycle strategies
- Importance of developing a portfolio of listed and unlisted patents
Speakers:
George W. Johnston, Hoffmann-LaRoche
Mark E. Waddell, Loeb & Loeb LLP
Thursday, October 11, 2012
10:45AM - 12:00PM - Analyzing Method Claims and the Madness Over Recent and Pending Inducement and Divided Infringement Cases
This panel will examine the link between inducement and divided infringement actions relative to methods of use claims for pharmaceutical patents.
Speakers:
Kathleen M. Gersh, Loeb & Loeb LLP
Edward M. Mathias, Axinn, Veltrop & Harkrider, LLP
Catherine Nyarady, Paul, Weiss, Rifkind, Wharton & Garrison LLP
-
Co-Chair, Life Sciences; Chair, Patent Litigation & Counseling -
